Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy

$BHVN
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $BHVN alert in real time by email

NEW HAVEN, Conn., April 17, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company, today announced that Nick Kozauer, M.D. has joined its executive leadership team as Senior Vice President for Clinical Development and Regulatory Strategy.  

Dr. Kozauer comes to Biohaven after an accomplished career at the U.S. Food and Drug Administration (FDA) where he served in positions of increasing responsibility, most recently as Director of the Division of Neurology 2 in the Office of New Drugs. During his tenure at the FDA, Dr. Kozauer led the division responsible for the regulation of all Investigational New Drug (IND) applications, New Drug Applications (NDAs), and Biological Licensing Applications (BLAs) for drugs being developed and/or approved for the treatment of neuroimmunologic conditions, epilepsies, migraine, stroke, traumatic brain injury, inner ear disorders, and other products.

Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, commented, "It is a great honor to welcome Dr. Kozauer to the Biohaven team. Dr. Kozauer is a true clinician-researcher who has supervised and reviewed the approval of over 15 marketed drugs during his tenure at the FDA. His knowledge and expertise in the regulatory process, as well as his deep experience in diseases including neuroimmunology and epilepsy, will only strengthen Biohaven's ability to efficiently advance our robust pipeline of compounds and deliver novel treatments in high unmet need areas in neuroscience for patients and their families. Dr. Kozauer has already positively impacted patient care during his time at the FDA and we are excited to have him on our team to help us innovate new therapies."

Prior to joining the FDA, Dr. Kozauer worked in academia at the Johns Hopkins Memory Center at the Copper Ridge Institute where he oversaw clinical care of patients with Alzheimer's disease and other dementias, and in private practice focusing on complex neuropsychiatric conditions. Dr. Kozauer completed his residency and fellowship training at Georgetown University Medical Center and Johns Hopkins, respectively, and received his M.D. from Rutgers-New Jersey Medical School.

Dr. Kozauer stated, "I am energized by the opportunity to work with such an experienced, dynamic, and patient-focused group of individuals pursuing groundbreaking science to develop a broad range of therapies for serious diseases with unmet medical needs. The team at Biohaven has demonstrated its ability to bring innovative medicines to patients and has an exciting portfolio including immune modulating agents, ion channel activators, myostatin targeting agent and other investigational drugs targeting ultra-rare diseases."

About Biohaven

Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies for people with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's experienced management team brings with it a track record of delivering new drug approvals for products for diseases such as migraine, depression, bipolar and schizophrenia. The company is advancing a pipeline of therapies for diseases with little or no treatment options, leveraging its proven drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia, myostatin inhibition for neuromuscular diseases, and brain-penetrant TYK2/JAK1 inhibition for immune-mediated brain disorders. Biohaven's portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates (ADCs), and extracellular target degrader platform technology (MoDE™) with potential application in neurological disorders, cancer, and autoimmune diseases.

Forward-looking Statements

This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the Food and Drug Administration; the timing and outcome of expected regulatory filings; complying with applicable U.S. regulatory requirements; the potential commercialization of Biohaven's product candidates; the potential for Biohaven's product candidates to be first in class therapies; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this new release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

MoDEs is a trademark of Biohaven Therapeutics Ltd.

Biohaven Contacts:

Jennifer Porcelli

Vice President, Investor Relations

jennifer.porcelli@biohavenpharma.com

201-248-0741

Mike Beyer

Sam Brown Inc.

mikebeyer@sambrown.com

312-961-2502

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biohaven-expands-executive-leadership-team-with-appointment-of-nick-kozauer-md-as-senior-vice-president-for-clinical-development-and-regulatory-strategy-301798320.html

SOURCE Biohaven Ltd.

Get the next $BHVN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BHVN

DatePrice TargetRatingAnalyst
2/11/2025$65.00Buy
Deutsche Bank
9/16/2024$57.00Buy
Jefferies
9/4/2024$55.00Outperform
Bernstein
7/24/2024$58.00Overweight
Morgan Stanley
2/16/2024$62.00Outperform
RBC Capital Mkts
2/6/2024$59.00Buy
UBS
12/22/2023$50.00Buy
H.C. Wainwright
12/8/2023$58.00Outperform
Robert W. Baird
More analyst ratings

$BHVN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

    WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

    $AVTX
    $BHVN
    $COLL
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300

    Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal antibody FcRn-targeting competition.Up to 84% reduction of total IgG was observed with a median reduction of 80% after subcutaneous weekly 1000 mg dosing in the ongoing Phase 1 study.Subcutaneous BHV-1300 achieved progressive reductions in IgG levels within hours of each weekly dose administration, and pharmacodynamic effects were sustained compared to baseline over the four-week period.Dose escalation with BHV-1300 continues in the study and plans to explore deeper reductions to characterize the potential r

    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results

    Announced acceptance and Priority Review by the United States Food and Drug Administration (FDA) of the new drug application (NDA) for troriluzole in all-genotype spinocerebellar ataxia; expected Prescription Drug User Fee Act (PDUFA) date in 3Q 2025.Cash, cash equivalents, marketable securities and restricted cash as of December 31, 2024 totaled approximately $489 million.Reported positive degrader data with multiple doses of BHV-1300 achieving up to 84% reduction of total IgG, with a median reduction of 80%, after subcutaneous weekly 1000 mg dosing in the ongoing Phase 1 study.Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of total IgG, differ

    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BHVN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BHVN
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$BHVN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BHVN
SEC Filings

See more

$BHVN
Leadership Updates

Live Leadership Updates

See more
  • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

    WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

    $AVTX
    $BHVN
    $COLL
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

    HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl

    $BHVN
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments

    Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China)Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy following his tenure as Director of the Division of Neurology 2 in the Office of New Drugs of the U.S. Food and Drug AdministrationTaldefgrobep alfa granted Fast Track Designation in SMADriving strong and consistent progress across six robust drug development platforms in 2023:in Kv7 activation, targeting Phase 2/3 study start in focal epilepsy and bipolar disorder in the second half of 2023;Phase 1 study initiation planned with potentially fi

    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BHVN
Financials

Live finance-specific insights

See more
  • Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

    Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes.Troriluzole also showed statistically significant superiority after both 1 and 2 years of treatment.Troriluzole achieved statistically significant superiority on 9 consecutive, prespecified primary and secondary endpoints.SCA patients treated with troriluzole showed a 50-70% slowing of disease progression, representing 1.5-2.2 years delay in disease progression over the 3-year study period.Biohaven plans to submit a New Drug Application (NDA)

    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

    Conference call and webcast to be held Monday, September 23, at 8:30am ET  NEW HAVEN, Conn., Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE (NCT06529146), a study designed in discussion with the US Food and Drug Administration (FDA), to assess the effectiveness of troriluzole in Spinocerebellar Ataxia. Conference Call and Webcast DetailsBiohaven will hold a live conference call and webcast Monday, September 23, 2024, at 8:30 a.m. Eastern Time. The live e

    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders

    Novel first-in-class, brain-penetrant, dual inhibitor of TYK2/JAK1 offers wide therapeutic index with TYK2 inhibition and high selectivity for JAK1 inhibition without the severely limiting adverse class effects of JAK2/JAK3 inhibitorsExclusive license covers global rights excluding China regionBiohaven anticipates initiating Phase 1 clinical development in 2023NEW HAVEN, Conn., March 22, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) today announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders. BHV-8000 (previously TLL-041) was

    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BHVN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more